CAS: 167354-41-8; Zosuquidar
- 英文名称Zosuquidar
- 中文名称(6R,7R)-7-[[2-[2-(氨基甲基)苯基]乙酰]氨基]-3-[[1-(羧甲基)四唑-5-基]硫甲基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸
- IUPAC名称(R)-1-(4-((1aR,6r,10bS)-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c][7]annulen-6-yl)piperazin-1-yl)-3-(quinolin-5-yloxy)propan-2-ol
- 其它别名(2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol
- CAS编号167354-41-8
- MFCD编号:MFCD09837761
- EINECS号:808-610-6
- FDA UNII编号:AB5K82X98Y
- 分子式:C32H31F2N3O2分子量:527.61
- 产品CID: 846690
- 同类组份化合物CAS167465-36-3 ( HCl)167354-41-8 (free base)
- 产品分类原料药 → 抗肿瘤药
物理性质
MSDS等安全信息
欧盟法规
C&L通报合成工艺路线路线简述
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2905122000-异丙醇
2905310000-1,2-乙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:EP-4058432-A1
优先权日:2019-11-14
标 题:Improved synthesis of kras g12c inhibitor compound
专利号:CN-108017615-A
优先权日:2017-12-16
标 题:Substituted quinoline tetrahydropyrrole methanol derivatives with activity of reversing drug resistance of tumor cells, synthesis method and application thereof
专利号:CN-108610327-A
优先权日:2018-04-19
标题:Substituted quinoline carbinol compound with activity of reversing drug resistance of tumor cells and its synthesis method and application
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Infed N, Smits SH, Dittrich T, Braun M, Driessen AJ, Hanekop N, Schmitt L. Analysis of the inhibition potential of zosuquidar derivatives on selected bacterial and fungal ABC transporters. Mol Membr Biol. 2013 Mar;30(2):217-27. doi: 10.3109/09687688.2012.758876. doi: 10.1007/s10549-011-1937-9. Epub 2012 Jan 8. doi: 10.1182/blood-2010-04-277269. Epub 2010 Aug 17.
4: Ruff P, Vorobiof DA, Jordaan JP, Demetriou GS, Moodley SD, Nosworthy AL, Werner ID, Raats J, Burgess LJ. A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol. 2009 Sep;64(4):763-8. doi: 10.1007/s00280-009-0925-9. Epub 2009 Feb 25. doi: 10.1016/j.leukres.2008.09.015. Epub 2008 Dec 23. doi: 10.1016/j.leukres.2008.09.020. Epub 2008 Oct 30. doi: 10.1186/1471-2407-8-51.
8: Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2007 Apr;48(4):708-15. Epub 2007 Mar 23. Epub 2006 Jan 24.
合成参考文献
参考文献:10.1155/2011/281651
摘要:Li H, Yan Z, Ning W, Xiao-Juan G, Cai-Hong Z, Jin-Hua J, Fang M, Qing-Duan W. Using Rhodamine 123 Accumulation in CD8+ Cells as a Surrogate Indicator to Study the P‐Glycoprotein Modulating Effect of Cepharanthine Hydrochloride In Vivo. BioMed Research International. 2011 Jan;2011(1). doi: 10.1155/2011/281651.
📝 需求与反馈
尽可能描述清楚需求与问题信息
